 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
174 News |  |
| «123» |
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
🤔Is there any better way to spend a weekend than learning EP fundamentals from a stellar faculty? 👩🏫 I think not! Register today for EP 101 !! (Twitter) - May 25, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Course directors Dr. Mark Estes and @narrowQRS join faculty to lead #EP101 covering ablation biophysics, basic entrainment & the post-pacing interval and more. #EPfellows – register today. https://t.co/XhHHSjYO53 (Twitter) - May 20, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
🗣️📢This. Is. It. EP101 is almost here!!! Join us for all new lectures, to build a strong EP foundation! Amazing faculty. Agenda of fundamentals. Worldwide access. Sign up today. Be there. (Twitter) - May 20, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
From basic stimulation protocols & electrophysiologic evaluations to catheter ablation accessory pathways & more, #EP101 for EP fellows with course directors Dr. Mark Estes & @narrowQRS will be taking place virtually on June 5-6. Register here: https://t.co/FfQVMArtjb (Twitter) - May 11, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
We’re looking forward to virtually bringing #EP101 to EP fellows on June 5-6. Course directors Dr. Mark Estes and @narrowQRS will be leading a comprehensive educational program for fellows. Register here: https://t.co/9PNsuC8YKc #MedEd #CardioEd #EPeeps (Twitter) - May 4, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Please join Dr. Estes and myself for the annual EP101 "rite of passage" conference for incoming EP Fellows!!! #VirtualLearning #AmazingFaculty (Twitter) - May 4, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
#EPFellows: Join us for #EP101 with course directors Dr. Mark Estes & @narrowQRS. Register here: https://t.co/UWQAVaWTKD #MedEd #CardioEd #EPeeps (Twitter) - Apr 21, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
A complex but valid point. And there have been past efforts of having HRS run things, but that didn't work out (and was more $$). I'll tell you that this EP101 course has no CRM device content and all content and faculty were left to the discretion of Dr. Estes and myself. (Twitter) - Apr 16, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Join course directors Dr. Mark Estes & @narrowQRS along with faculty @ed_gerst, @krishkancharla, @bradleyknight, @drgregmichaud, @mrobinsonep, @zo_ep2, Dr. Asirvatham, @SilviaPriori1, Dr. Barrett & Dr. Jackman for #EP101: https://t.co/6hQP7STiZT (Twitter) - Apr 15, 2021
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Journal: Validation of a sensitive and specific LC-MS/MS Method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. (Pubmed Central) - Apr 1, 2021
By comparing to the intravenous (IV) administration, it was found respective bioavailabilities of ~15% for GLY/Magnair and ~22% for Seebri Breezhaler. The bioanalytical reliability was also demonstrated by satisfactory incurred sample reanalysis performance.
- Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
[VIRTUAL] Exacerbations in Patients with Chronic Obstructive Pulmonary Disease Treated with Nebulized Glycopyrrolate versus Other Long-Acting Muscarinic Antagonists: A U.S. Healthcare Administrative Database Analysis () - Mar 14, 2021 - Abstract #ATS2021ATS_1403;
Compared to patients new to LAMA products, patients newly initiated GLY had a greater reduction in both moderate and severe exacerbations during 6-month after treatment initiation compared to 6-month prior. This retrospective analysis was limited by the small cohort size and short observation window.
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Drugs for COPD. (Pubmed Central) - Dec 30, 2020
This retrospective analysis was limited by the small cohort size and short observation window. No abstract available
- | Veramyst (fluticasone furoate nasal spray) / GSK
Journal: Comparison table: Inhaled long-acting bronchodilators for treatment of COPD. (Pubmed Central) - Dec 30, 2020
No abstract available No abstract available
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you so much Dr.Cooper! I am so looking forward to this year’s EP 101! (Twitter) - Dec 3, 2020
- Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
[VIRTUAL] Impact of Cleaning and Supplemental Maintenance Instructions of the Magnair Vibrating Membrane Nebulizer on Device Nebulization Times (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_5127;
These results highlight the consistency of Magnair nebulization and delivery of drug over continuous use with regular cleaning, irrespective of backwashing the aerosol head. When the recommended cleaning is performed as recommended, the Magnair device still delivers the drug within specifications for up to 60 days, and the supplemental backwash procedure is not necessary.
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: Interesting micro-climates regarding ethnicity in various professions. In EP101 course in recent years, there has been disproportionately high representation of minorities. But dramatic underrepresentation of women - need to encourage more women to pursue EP! 💓🏃♀️ (Twitter) - Jun 9, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Great explanations by @Zo_EP2! Virtual education at its best. Thanks @BSCCardiology @HRSonline and course directors @narrowQRS & Dr. Mark Estes in making virtual #EP101 possible for #Epeeps this year. Fantastic lectures by faculty @DrBradleyKnight @drsuneet @DrGregMichaud (Twitter) - May 31, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
So glad you joined us today! Tomorrow will be a great program as well! Many thanks to @BSCCardiology for quickly putting together a covid-19 version of EP 101!! (Twitter) - May 31, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Virtual #EP101 with Dr’s Estes, @narrowQRS @DrBradleyKnight Such a great course! #EPFellow #VAV #VAAV (Twitter) - May 30, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you for making this possible @BSCCardiology! Great educational lectures! also, very nice ECG tie Dr. Cooper! :) #ep101 Thank you @narrowQRS @DrBradleyKnight Dr. Estes, Dr. Asirvatham! (Twitter) - May 30, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
Trial completion, Enrollment change: A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease. (clinicaltrials.gov) - May 3, 2020
P4, N=46, Completed, Sponsor: Sunovion Respiratory Development Inc.
When the recommended cleaning is performed as recommended, the Magnair device still delivers the drug within specifications for up to 60 days, and the supplemental backwash procedure is not necessary. Recruiting --> Completed | N=20 --> 46
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
⋄⋄✧HI!⋄⋆⋅⋆⋄✧⋄⋆⋅⋆⋄🍃RUN ep 101⚡️🇰🇷💜✨⋄⋆⋅⋆⋄✧⋄⋆⋅⋆⋄✧⋄⋆⋅⋆⋄✧⋄⋆⋅ ☘️☄️100JIN☄️☘️🌿🌙SEOK100💫🌿••#BTS2020 #BIGHIT #RunBTSEp101 🌜🌛🌸🌾🍃⚡️🌈🔥🌿🎍🍁🌻😍 (Twitter) - Apr 22, 2020
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Journal: Glycopyrrolate (Lonhala Magnair) for Treatment of Chronic Obstructive Pulmonary Disease. (Pubmed Central) - Mar 22, 2020
Recruiting --> Completed | N=20 --> 46 No abstract available
- Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Impact of Cleaning and Supplemental Maintenance Instructions of the Magnair Vibrating Membrane Nebulizer on Device Nebulization Times (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area F) - Mar 15, 2020 - Abstract #ATS2020ATS_7678;
These results highlight the consistency of Magnair nebulization and delivery of drug over continuous use with regular cleaning, irrespective of backwashing the aerosol head. When the recommended cleaning is performed as recommended, the Magnair device still delivers the drug within specifications for up to 60 days, and the supplemental backwash procedure is not necessary.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
Clinical, Journal: Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. (Pubmed Central) - Mar 14, 2020
High levels of satisfaction, confidence, and ease of use were reported with the eFlow CS nebulizer in this study. These findings support the use of the eFlow CS for maintenance treatment of COPD with glycopyrrolate inhalation solution.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Even if you didn’t attend #EP101 last year, you can download the @HRSonline #HRS365 app - the lectures are stored there. They can be streamed from or downloaded to your phone #EPeeps (Twitter) - Feb 6, 2020
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
If you attended EP 101, you should have received a username and password. The lectures are fantastic. (Twitter) - Feb 5, 2020
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
One of the perks of commuting for my EP rotation is listening to #EP101 podcasts hosted by @narrowQRS and Dr. Estes. Today’s lecture- ‘Techniques to Differentiate SVTs’ by @DrBradleyKnight #ThereIsAlotToLearn #PSVT (Twitter) - Feb 5, 2020
- Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
Enrollment open: A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease. (clinicaltrials.gov) - Feb 5, 2020
P4, N=20, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
These findings support the use of the eFlow CS for maintenance treatment of COPD with glycopyrrolate inhalation solution. Active, not recruiting --> Recruiting
- Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
Enrollment closed: A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease. (clinicaltrials.gov) - Jan 7, 2020
P4, N=20, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
I've said how much I'd love to give a PPT skills talk at HRS! (I have done a session on this at the 3T breakout session of the EP101 fellows course) Not everyone should have to just figure it out on their own! (Twitter) - Jan 7, 2020
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
New P4 trial: A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease. (clinicaltrials.gov) - Nov 11, 2019
P4, N=20, Not yet recruiting, Sponsor: Sunovion Respiratory Development Inc.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Not enough understanding of lead design and how it plays such a vital role in lead failure.. have worked with @MDT_Cardiac in the past to speak on this topic. Maybe would be a good topic for @BSCCardiology EP101. (Twitter) - Jul 14, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Looking forward to more learning and growing! Thanks for teaching us @ #EP101 (Twitter) - Jun 3, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Great seeing our incoming 2019 UCSF EP fellows @DrEJKim @MdSarcon and Dave R all at EP101. Looking forward to working with all of you for the next 2 years! (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
What an awesome conference! #EP101 is truly a rite of passage for all budding electrophysiologists. Thank you all faculty and @BSCCardiology! And special thanks to 3T team and mentors!! Drs. Estes @narrowQRS @Zo_EP2 @DrGregMichaud @Ed_Gerst @DrBradleyKnight @ACCCardioEd (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Pleasure meeting you today @MdSarcon #EP101 (Twitter) - Jun 2, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: Thank you so much Dr.Estes and Dr.Cooper @narrowQRS and all the faculties! Such a privilege to learn from all the gr8 teachers in the field-reinforced my decision to pursue EP! @Ed_Gerst @Zo_EP2 @DrGregMichaud @drsuneet @cooper_dh @JRWinterfield @DrBradleyKnight #ep101 #womeninep (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you @narrowQRS and Dr. Estes for the opportunity to be faculty at EP 101. Amazing turnout of brilliant new EP minds. What an incredible program that is truly a rite of passage for the incoming EP fellows. @BSCCardiology @nycrhythmdoc @cooper_dh @drsuneet @DrBradleyKnight (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Extremely thankful to have attended the #EP101 course directed by Dr Estes and @narrowQRS The faculty consisting of @DrFerminGarcia @DrGregMichaud @drsuneet @JRWinterfield @cooper_dh @Drdevignair @DrBradleyKnight and others was fantastic. Cannot recommend this course enough! (Twitter) - Jun 2, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Easy to get excited about EP w/ engaging educators & welcoming #EPeeps community. @BSCCardiology knocked it out of the park & learning from those I've followed for yrs was amazing @narrowQRS @cooper_dh @JRWinterfield @DrBradleyKnight @DrGregMichaud +many more. Thank you! #EP101 (Twitter) - Jun 2, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
A heartfelt thank you to all the amazing teachers who made complex topics understandable, and fueled the fire in the upcoming #EPfellow #EP101 @bostonsci @narrowQRS @drsuneet @JRWinterfield @DrFerminGarcia @cooper_dh @Ed_Gerst @sonnyjackman @DrBradleyKnight and so many other! (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you @DrBradleyKnight @narrowQRS @DrFerminGarcia @drsuneet for wonderful lectures over the last 4 days @bostonsci EP101 (Twitter) - Jun 2, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
This is correct. The discussion drifted away from the original question of how one can see QS uni signal and not be at SOO. This is common (Dr Jackman just discussed this at #EP101 !) and does not directly imply intramural source. I'll post a good example later today! (Twitter) - Jun 2, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: At @BSCCardiology #EP101 fellows conference, the male predominance of incoming EP fellows is striking. Need to find solutions to encourage more women to enter this amazing field! So many amazing opportunities! @HRSonline @AndreaRussoEP (Twitter) - Jun 2, 2019
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: Wonderful experience presenting a case at EP101, as part of the 3T (Teaching Tomorrow’s Teachers) EP Program. Thanks to all the mentors/instructors involved. #3TEP @DrBradleyKnight Dr.MarkEstes @narrowQRS @BSCCardiology @ACCinTouch (Twitter) - Jun 2, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
@Zo_EP2 presents beautiful review of rationale for and implementation of #ablateVT in various substrates during #EP101. @BSCCardiology @narrowQRS @True_EP @Ed_Gerst @JDMossMD @Dr_Santangeli @rdschaller (Twitter) - Jun 1, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
#EP101 #EPeeps @narrowQRS @cooper_dh @DrFerminGarcia @Ed_Gerst @DrBradleyKnight @DrGregMichaud @JRWinterfield @drsuneet @Drdevignair Enjoying the course! Thanks for imparting your knowledge! (Twitter) - Jun 1, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Learning from the experts #EP101 @bostonsci @narrowQRS @DrGregMichaud @DrBradleyKnight @GuruKowlgi (Twitter) - Jun 1, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
I handed our fellow (now at EP 101) Dr. Knight’s SVT diagnosis paper and said, “when you can explain this to me, you’re done with fellowship.” (Twitter) - May 31, 2019